KRAS and neoplasm: The combination of anti-EGFR-mAB and siRNA targeting KRAS effectively suppressed KRAS protein expression in CRC cell lines, and reduced tumor volume and tumor weight effectively in a mouse implantation tumor model with cetuximab resistance mutation [195].